|
Kolltan licenses antibodies from founder
Hartford Business The so-called anti-KIT receptor tyrosine kinase antibodies were developed in the labs of Joseph Schlessinger at Yale University — a Kolltan founder — and Sachdev Sidu, a geneticist at the University of Toronto and Kolltan adviser. Terms of the deal … |
This is Local London |
Obinutuzumab routs rituximab in older chronic lymphocytic leukemia patients
The Oncology Report In the CLL11 study of older chronic lymphocytic leukemia (CLL) patients with coexisting medical problems, obinutuzumab (Gazyva) pushed the overall response rate to 78%, compared with 65% with rituximab (Rituxan) (P less than .0001). Both drugs were … Obinutuzumab Tops Rituximab in CLL TrialCancer Network Dr. Goede on Obinutuzumab Versus Rituximab in CLLOncLive New Drug Combo Potentially ‘Practice Changing’ in CLLMedscape Healio –PR Newswire (press release) all 15 news articles » |
|
NKT Therapeutics’ Identifies Novel anti-iNKT Antibodies for Depleting or …
PR Newswire (press release) WALTHAM, Mass., Dec. 9, 2013 /PRNewswire/ — NKT Therapeutics (NKTT) today presented research results with NKT14 and NKT14m, monoclonal antibodies designed to deplete (NKT14) or activate (NKT14m) murine iNKT cells. The results from these … |
|
Janssen Oncology Data to be Presented at 2013 American Society of …
FiercePharma Combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP): updated results from a phase 1b study in treatment-naïve patients with CD20-positive B-cell non-Hodgkin’s lymphoma (NHL). (Abstract 852). |
Kolltan Pharmaceuticals licenses anti-KIT antibodies from University of TorontoPharmaceutical Business ReviewKolltan Pharmaceuticals, a privately held biopharmaceutical company, has signed a licensing agreement with the University of Toronto for anti-K…
|
Interim Phase IIa Results for Spiegelmer ® Olaptesed Pegol (NOX-A12) in CLL …
Business Wire (press release) In the first study, olaptesed was administered to relapsed chronic lymphocytic leukemia (CLL) patients in combination with bendamustine and rituximab. In the second study, olaptesed was combined with bortezomib and dexamethasone in patients with … |
OncLiveObinutuzumab Regimen Slows CLL Compared With Standard TherapyOncLivePatients with chronic lymphocytic leukemia (CLL) and major comorbidities had significantly better outcomes when treated with the anti-CD20 monoclonal antibody obinutuzumab (Gazy…
|
New Drug Combo Potentially ‘Practice Changing’ in CLL
Medscape NEW ORLEANS — More clinical details have been reported showing how the new monoclonal antibody obinutuzumab (Gazvya, Roche) was superior to the stadard therapy rituximab (Rituxan, Roche) when both were used in combination with chlorambucil in … |
Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent …Business Wire (press release)Study 101-09 is a Phase 2, open-label, single-arm efficacy and safety study of idelalisib in patients with previously treated iNHL that is refra…
WalesOnline |
Dr. Goede on Obinutuzumab Versus Rituximab in CLL
OncLive Valentin Goede, MD, from the University Hospital Cologne and the German CLL Study Group, discusses the efficacy findings from the stage 2 CLL11 study that examined obinutuzumab (Gazyva; formally GA101) plus chlorambucil in patients with chronic … New Drug Combo Potentially ‘Practice Changing’ in CLLMedscape Improved Efficacy, Limited Toxicity of Targeted Therapies Brighten the Future …SYS-CON Media (press release) ‘Exciting’ leukaemia drug trial results published after Welsh hospital trialsWalesOnline |